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Abstract 20 
In this study we present a novel silver complex of hyaluronan-lipoate (SHLS12) in a gel-state form. 21 
NMR analysis, conductometry and elemental analysis demonstrated stable non-covalent 22 
interactions between silver ions and the polysaccharide-lipoate backbone, whereas rheological 23 
investigations confirmed its gel-like physical-chemical behavior. Biological studies showed the 24 
ability of SHLS12 to exert a straightforward activity against different bacterial strains grown in 25 
sessile/planktonic state. The biocompatibility was also proved towards two eukaryotic cell lines. By 26 
considering both its ability to preserve antibacterial properties when exposed to the serum protein 27 
BSA and its low susceptibility to be degraded by hyaluronidase enzyme, this novel complex may be 28 
considered as a promising biomaterial for future in vivo applications.  29 
 30 
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1. Introduction 39 
The extended use of silver and silver-derivatives has since long time gained appeal because of 40 
their ability to exert antibacterial activity towards a wide number of bacteria strains. This surely 41 
represents an undeniable advantage for the healthcare worldwide, considering the evolution of 42 
microorganisms, in particular their resistance against multiple antibiotics.(Klasen, 2000) With the 43 
advancement of nanotechnology, nano-crystalline forms of silver metal can be easily obtained by 44 
exploiting reliable protocols so as to tune their dimension and shape.(Gunasekaran, Nigusse, & 45 
Dhanaraju, 2011) Nevertheless, it is a hitherto diffuse opinion considering silver ions (Ag+) as 46 
responsible for the antimicrobial activity.(Knetsch & Koole, 2011) Indeed, the work of Xiu et al. 47 
gave an excellent contribution to clarify this question, inferring that Ag+ is the definitive molecular 48 
toxicant.(Xiu, Zhang, Puppala, Colvin, & Alvarez, 2012) In this scenario, Ag+ ions formed by 49 
oxidation of the (reduced) metal core form a silver ion corona surrounding silver nanoparticles; 50 
physical contact of bacteria with such Ag+ ions, dissolved and released in the environment 51 
surrounding the nanoparticles, is at the root of their toxicity towards prokaryotic cells. As a 52 
consequence, the development of innovative biomolecules to capable of firmly coordinating silver 53 
ions in a non-toxic form for the eukaryotic cells and so exploitable in biomedical products is a key 54 
challenge.  55 
A noteworthy candidate to this purpose is hyaluronan (HA). HA is a polysaccharide naturally 56 
present in the human body and it is composed of the regularly alternating repeat of β (1→4) linked 57 
D-glucuronic acid and β (1→3) linked D-N-acetylglucosamine. It is widely considered a very 58 
interesting biopolymer because of its peculiar physical, chemical and biological properties.(Collins 59 
& Birkinshaw, 2013) There are very few studies concerning the ability of HA to foster the binding 60 
and stabilization of silver in different chemical forms compared to other biopolymers, e.g. chitosan 61 
or alginate.(S. J. Lee et al., 2014), (Yang, Zheng, Han, Jiang, & Chen, 2015) For example, Abdel-62 
Mohsen et al. fabricated HA fibers via wet-spinning technique, which were able to form and to 63 
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stabilize silver nanoparticles.(Abdel-Mohsen et al., 2012) Chudobova et al. demonstrated the 64 
formation of hyaluronate-silver complexes after the addition of silver nitrate to a solution of 65 
HA.(Chudobova et al., 2013) 66 
The basic idea for the present work is to exploit a hyaluronan-lipoate derivative (known as 67 
Lipohyal)(Picotti et al., 2013) to obtain a stable hyaluronan-silver complex. Lipohyal (Figure S1 of 68 
the Supplementary Material) is a mixed ester of lipoic and formic acids of hyaluronan which was 69 
demonstrated to possess radical scavenging properties, high resistance versus enzymatic 70 
degradation by hyaluronidase and the possibility to be cross-linked by means of UV irradiation in 71 
order to obtain a stable hydrogel with peculiar viscoelastic properties.(Picotti et al., 2013) 72 
Lipoate is a disulphide derivative of octanoic acid and it has been well known to be a 73 
powerful tool for the treatment and prevention of many pathologies involving a defect of the 74 
oxidative-reductive cellular pathway.(Bustamante, 1998),(Kagan et al., 1992) Ramachandran et al. 75 
developed a lipoate-silver nanoparticles complex to be used as an adjuvant in cancer radiotherapy 76 
and also to enhance the anti-tumor activity of gamma radiation, but antibacterial studies were not 77 
reported.(Ramachandran & Krishnan Krishnan Nai, 2011)  78 
In the present paper we present a novel silver complex of sodium hyaluronate-lipoate 79 
(SHLS12) capable to coordinate silver ions. SHLS12 is produced by introducing slight 80 
modifications in the synthetic pathway of Lipohyal, mainly devoted to avoid the presence of 81 
formate ester residues linked on the polymeric chain. This compound is shown to advantageous 82 
provide the combination of distinctive and novel physical-chemical properties with the antibacterial 83 
features of silver ions in a non-toxic form for the eukaryotic cells.  84 
 85 
2. Materials and Methods 86 
2.1 Materials. The sodium hyaluronate (Phylcare Sodium Hyaluronate extra LW) employed 87 
in this study was purchased from Biophil Italia Spa (MW ≈ 100 - 400 kDa). Sodium hyaluronate-88 
 5 
lipoate (SHL), prepared as previously reported, (Picotti et al., 2013) had a degree of substitution of 89 
0.3 as determined by NMR analysis with a corresponding molar mass (MW) of the repeating unit 90 
equal to 457.5 g mol-1. Chemical identity of SHL was assessed by NMR, with reference to 91 
published results.(Picotti et al., 2013). Hyaluronidase (type IV-S from bovine testes, H 3884 - 500 92 
mg, batch 098K7352, 2140 units / mg, lyophilized powder) was purchased from Sigma Aldrich. 93 
Neutral Red, Thiazolyl Blue Tetrazolium Bromide (MTT), phenazine methosulfate (PMS), bovine 94 
serum albumin (BSA) powders, fetal bovine serum, Luria-Bertani (LB) broth, LB Agar, Brain Heart 95 
Infusion (BHI) broth, silver acetate (≥ 99.0%) and phosphate buffered saline (PBS) were all 96 
purchased from Sigma-Aldrich (Chemical Co. USA). Dulbecco’s Modified Eagle’s Medium, fetal 97 
bovine serum, penicillin, streptomycin and glutamine solutions were purchased from EuroClone, 98 
Italy. All chemicals and reagents were of the highest purity grade commercially available.  99 
2.2 Characterization methods. NMR analyses were performed with a Bruker AVANCE 400 100 
spectrometer, equipped with an indirect multinuclear gradient z probe (ID 5 mm BBI 1HBB z-101 
GRAD). UV-Vis measurements were performed on Varian Cary 50 spectrophotometer. Elemental 102 
analysis was provided as a service by REDOX srl - Viale Stucchi, Monza -MB.  103 
2.3 Synthesis of SHLS12. The synthesis of the silver complex of sodium hyaluronate-lipoate 104 
(SHLS12) was performed simply by silver acetate addition (0.098 g; MW: 116.91 g mol-1; 0.58 105 
mmol, ratio with lipoic residue 1/1 mol/mol) to a 0.2% w/v solution of SHL (1 g anhydrous, 457.5 g 106 
mol-1, 2.18 mmol. in 0.5 L). A gel formation was observed after about two hours.  107 
2.4 Rheological measurements. It has been used a control stress rheometer Anton Paar MCR 108 
30, equipped with cone/plate (50 mm / 1°) and parallel plate (SPP 25 mm / gap 1 mm) measurement 109 
systems. Studies were carried out on SHLS12 complex (0.2% w/v), sodium hyaluronate (0.2% 110 
w/v), SHL (0.2% w/v), SHL after Ag removal and sodium hyaluronate (0.2% w/v) + silver. For the 111 
latter it was added the same quantity of silver acetate used in SHLS12 synthesis, and the same 112 
swelling time was considered. All solutions were prepared in acetate buffer 30 mM (pH = 5.4). All 113 
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samples were preliminarily characterized at 25 °C, while degradation studies were conducted at 37 114 
°C for at least 2 hours, under continuous flow. Gelation kinetics was performed at 25 °C: silver 115 
acetate solution was added to 0.2% w/v of polymer solution (sodium hyaluronate or SHL) for each 116 
measurement. After 4 minutes under magnetic mixing, the samples were transferred on 117 
measurement system and test starts. 118 
2.5 Enzymatic degradation. Enzymatic degradation studies were carried out with bovine 119 
testicular hyaluronidase: the molar ratio of polysaccharide / enzyme used was 6150:1 (referred to 120 
disaccharide unit of SHL). Degradation kinetic was conducted adding 70 μL of hyaluronidase 121 
concentrated solution to 1 mL of polymeric solutions or swelled complex, thermostated at 37 °C. 122 
The mixture was stirred for 30 seconds and then transferred to the measuring system. Rheological 123 
measurements started after 3 minutes from mixing. 124 
2.6 Antibacterial tests. The antibacterial activity of SHLS12 was evaluated using strains of 125 
Escherichia coli (ATCC® 25922TM), Staphylococcus epidermidis (ATCC® 12228TM), 126 
Staphylococcus aureus (ATCC® 25923TM) and Pseudomonas aeruginosa (ATCC® 27853TM). 127 
2.6.1 Growth inhibition assay. Growth inhibition assay was performed according to the 128 
protocol described in (Sacco, Travan, Borgogna, Paoletti, & Marsich, 2015) with slight 129 
modifications. SHLS12 solution (0.2% w/v) was prepared by adding SHLS12 in LB broth and 130 
vigorously vortexed for 30 seconds in order to obtain a clear and homogeneous dispersion of the 131 
polymer in such medium. Bacterial suspensions were prepared by adding 20 µL of bacteria, 132 
preserved in glycerol, to 5 mL of LB broth. The obtained suspensions were incubated overnight at 133 
37 °C. After 24 h, 500 µL of bacterial suspension was diluted in 10 mL of broth and grown up for 134 
90 min at 37 °C in order to restore an exponential growth phase. Bacterial concentration was 135 
measured by means of optical density (OD) at 600 nm. After centrifugation (3 500 rpm, 5 min), 136 
supernatants were removed and bacteria were resuspended with either SHLS12 solution in LB broth 137 
or LB broth to obtain a final concentration of 5 X 106 bacteria mL-1. In the case of evaluation of the 138 
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BSA influence on SHLS12 activity, bacteria were resuspended in LB broth added with either BSA 139 
(40 g L-1) or BSA and SHLS12 (40 g L-1 and 0.2% w/v, respectively). All bacteria strains were then 140 
incubated at 37 °C for 4 h in shaking conditions (140 rpm). At the end of incubation, bacterial 141 
suspension was serially diluted in PBS buffer (from 10-1 to 10-5) and 25 µL of each suspension were 142 
plated on LB agar. After overnight incubation at 37 °C, the colony forming units (CFUs) were 143 
counted. Outcomes were compared with the suspension of bacteria grown in liquid medium as 144 
control. 145 
2.6.2 Biofilm formation. Bacterial suspensions of S. aureus and P. aeruginosa were prepared 146 
by adding 20 µL of bacteria, preserved in glycerol, to 5 mL of BHI broth plus 3% w/v sucrose. The 147 
obtained suspensions were incubated overnight at 37 °C. After 24 h, bacteria were diluted 1:100 in 148 
the same broth and plated (300 µL/well) into 24-well plates. For confocal laser scanning 149 
microscopy analyses, bacteria were plated on sterile 13 mm tissue culture coverslips (Sarstedt, 150 
USA) laid down on the bottom of the culture plate wells. Plates were incubated at 37 °C for 24 h to 151 
allow biofilm formation. After 24 h, broth was removed and formed biofilm was carefully rinsed 152 
twice with 100 µL of sterile PBS in order to remove planktonic cells. 300 µL of PBS containing 153 
0.2% w/v of SHLS12 were deposited on the bacterial layer. Biofilms were then incubated at 37 °C 154 
and MTT assay was performed according to the following protocol after 4 and 24 h of incubation. 155 
2.6.3 Viable biomass assessment. The test was performed according to the protocol described 156 
elsewhere.(Brambilla et al., 2012) Briefly, MTT stock solution was prepared by dissolving 5 mg 157 
mL-1 of MTT powder in sterile PBS. PMS stock solution (0.3 mg mL-1) was prepared by dissolving 158 
PMS powder in sterile PBS. Solutions were further filtered (0.22 µm filters, BioSigma, Italy) and 159 
stored at 2 °C in light-proof vials until the day of the experiment, when a fresh measurement 160 
solution (FMS) was prepared by mixing 0.5 mL of MTT stock solution, 0.5 mL of PMS stock 161 
solution, and 4 mL of sterile PBS. DMSO was used as lysing solution (LS). After the biofilm 162 
incubation period, SHLS12 and PBS were gently removed from the plates and each well was 163 
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carefully rinsed three times with 100 µL of sterile PBS in order to remove non-adherent cells. 200 164 
µL of FMS solution were placed into each well and the plates were incubated for 3 h under light-165 
proof conditions at 37 °C. The FMS solution was then gently removed and formazan crystals were 166 
dissolved by adding 200 µL of LS to each well. Plates were additionally stored for 1 h under light-167 
proof conditions at room temperature and then 100 µL of the solution were transferred into the 168 
wells of 96-well plates. The absorbance of the solution was measured using a spectrophotometer 169 
(FLUOStar Omega-BMG Labtech) at a wavelength of 550 nm. Outcomes were expressed as OD 170 
units. 171 
2.7 Confocal laser scanning microscopy (LSCM). LSCM analyses were addressed at 172 
detecting viability of bacteria in the biofilm mass. FilmTracer Live/Dead biofilm viability kit 173 
(Invitrogen™) was used. Dead cells were stained by propidium iodide (red fluorescence - λex 514 174 
nm; λem 590 nm), whereas living cells by SYTO® 9 (green fluorescence - λex 488 nm; λem 515 nm). 175 
Staining was performed according to the manufacture’s protocol on biofilms grown on coverslips as 176 
described above. Images were acquired on a Nikon Eclipse C1si confocal laser scanning 177 
microscope with a Nikon Plan Fluor 20X as objective. Stacks of images were analyzed using 178 
ImageJ software. 179 
2.8 Cell culture. Mouse fibroblast-like NIH-3T3 (ATCC® CRL1658) and immortalized 180 
human keratinocyte HaCaT (kind gift of Dr. Chiara Florio, University of Trieste) cell lines were 181 
used for the in vitro experiments. Both cell lines were cultured in Dulbecco’s Modified Eagle’s 182 
Medium high glucose, 10% heat-inactivated fetal bovine serum, 100 U mL-1 penicillin, 100 µg mL-1 183 
streptomycin and 2 mM L-glutamine in a humidified atmosphere of 5% CO2 at 37 °C. 184 
2.9 Biocompatibility studies. In vitro cytotoxicity of SHLS12 was evaluated by using 185 
Neutral Red assay on both NIH-3T3 and HaCaT cells. 20 000 cells were plated on 24-well plates 186 
and, after complete adhesion, culture medium was changed with 300 µL of fresh medium. The 187 
cytotoxicity test was performed by direct contact of the cells with SHLS12 (50 µL of a solution 188 
 9 
0.2% w/v) laid down on filter papers, (16 mm2 as surface) placed in the middle of each well. As a 189 
positive control material, poly(urethane) films containing 0.25% zinc dibuthyldithiocarbamate 190 
(ZDBC) were used. As negative control material, plastic poly(styrene) sheets were used. Untreated 191 
cells (without any contact-material) were also considered as additional control. After 24 and 72 h, 192 
Neutral Red assay was performed according to the manufacture’s protocol. Each material test was 193 
performed in triplicate. Cytotoxicity was expressed as percentage of viability by normalizing the 194 
OD540 nm of treated cells to the OD540 nm of the untreated cells. 195 
2.10 Statistical analysis. Data are expressed as means and standard deviations (SD). 196 
Statistical analysis was performed using Student’s t test, and a P value of < 0.05 was considered 197 
statistically significant. 198 
3. Results and discussion 199 
3.1 SHLS12: physical-chemical properties. The chemical characterization of the product 200 
was initially carried out by NMR analysis, to reveal the interaction between SHL and silver ions. In 201 
particular, the 1H-NMR spectrum in D2O of SHLS12 in comparison with SHL evidences signal 202 
modifications at the lipoic ring level (Figure S2 of the Supplementary Material). More in detail, the 203 
two protons in 6 position are down field shifted by presence of silver (H6a from 2.45 to 2.72  ppm, 204 
H6b from 1.95 to 2.13 ppm) while the other protons, closer to the ester bond, are less affected. This 205 
suggests that an interaction between the metal and the lipoic ring occurs. Moreover, a drift of the 206 
anomeric signal is also observed, which is compatible with a conformational stiffening of the 207 
polymer chain, as suggested by the signal broadening.  208 
 Assessing a possible role of the acetate moiety is of pivotal importance for the better 209 
understanding of the structure of the complex. NMR can help evaluating whether the acetate ion is 210 
somehow bound to the Ag+-containing polymer system: upon increasing magnetic field strength the 211 
signals of diffusive species decrease more rapidly than those of the groups bound to the polymer 212 
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(DOSY experiments). When the proton signals of the methyl group in acetate and in N-213 
acetylglucosamine are compared with that of HDO (used as standard as diffusive species in 214 
solution), it was observed that the former decreases proportionally to that of HDO, while the 215 
intensity of that relative to N-acetylglucosamine is constant. It can be concluded that acetate is 216 
freely diffusible and not bound to the polymer domain (Figure S3 of the Supplementary Material). 217 
The chemical and physical nature of silver in such biomaterial is crucial in relation to the 218 
biological activity of the complex. In order to determine whether silver was present as Ag+ or in 219 
nanoparticle form, UV-Vis measurements were performed. Spectrum in Figure 1A shows that silver 220 
in SHLS12 is not in nanoparticle form because the typical plasmon resonance band at around 410 221 
nm is absent. Moreover, by adding sodium iodide (NaI) as Ag+-precipitating molecule, the gel 222 
structure is destroyed and a biphasic system is recovered, with a precipitate observed at the bottom. 223 
NMR analysis of the supernatant solution (Figure 1B) points out a pattern of signals perfectly 224 
matching those of native SHL, thus demonstrating the full reversibility of interaction with no 225 
permanent chemical modification. This evidence was also confirmed by rheological measurements 226 
(Figure 2B). 227 
 228 
 229 
Figure 1. (A) UV-Vis spectra of SHLS12 compared to silver nanoparticles; (B) 1H-NMR spectra of 230 
Sodium Hyaluronate-Lipoate (SHL), SHLS12 and SHLS12 after silver removal. 231 
 232 
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The ratio between the polymer and the metal was determined by means of conductometry. 233 
SHL solution (10 mL; DS: 0.3 mol/mol; concentration 0.2% w/v ≈ 0.043 mM) was prepared and 234 
silver acetate solution (45.2 mM) was drop wise added to it. Figure S4 reports the conductivity 235 
values as a function of the volume of silver acetate solution added. The plot shows that the 236 
conductivity trend undergoes a slope variation. By the linear fitting of experimental data, the point 237 
of discontinuity was obtained corresponding to a ratio silver/lipoic residue of 1:1. Elemental 238 
analysis (Theoretical: Silver: 6.9%; Sulphur: 4.1% - Found: Silver 6.6%; Sulphur 3.9%) on the 239 
isolated product from precipitation with acetone confirmed the 1:1 ratio.  240 
A rheological investigation was performed to point out differences among the various 241 
systems. While sodium hyaluronate and its derivative SHL showed a solution-like behavior, 242 
SHLS12 behaved like a gel. These results are highlighted in Figure 2A,B where the mechanical 243 
spectra and flow curves are shown. A further control (sodium hyaluronate + silver) was added so as 244 
to verify the role of metal with the polymer. We demonstrated that when silver was added to 245 
sodium hyaluronate a solution-like behaviour was observed in both cases. In order to verify the gel 246 
nature of SHLS12, a gelation kinetics was performed and the outcomes are shown in Figure 2C. We 247 
observed the intersection between the storage and loss moduli about after 20 minutes of gelation. 248 
Later, the storage modulus was verified to be almost one order of magnitude higher with respect to 249 
the loss modulus. This condition allows considering SHLS12 as a “strong gel”. Conversely, a 250 
solution-behavior was demonstrated when silver was added to sodium hyaluronate. Indeed, the loss 251 
modulus was found constant on time. The straightforward explanation is that silver ions may act as 252 
non-covalent linking points between sulphur atoms of the lipoic residues of the different chains 253 
favoring the formation of a tridimensional network.  254 
 12 
 255 
Figure 2. Mechanical spectra (A) of SHLS12 (red full - G' - and open - G'' - circles), Sodium 256 
Hyaluronate-Lipoate (blue squares), Sodium Hyaluronate (black triangles) and Sodium Hyaluronate 257 
+ silver (orange circles) loss moduli. Flow curves (B) of SHLS12 (red circles), Sodium 258 
Hyaluronate-Lipoate (blue squares), Sodium Hyaluronate (black triangles), Sodium Hyaluronate + 259 
silver (orange circles) and Sodium Hyaluronate-Lipoate after Ag removal (cyan triangles). Gelation 260 
kinetics (C): storage (red circles) and loss (green circles) moduli over time of SHLS12; Sodium 261 
Hyaluronate + silver (orange circles) loss modulus. 262 
 263 
Enzymatic degradation tests were conducted to evaluate the complex resistance, in 264 
comparison with sodium hyaluronate and SHL: the results are shown in Figure 3. At the 265 
substrate/enzyme ratio tested, hyaluronan is quickly degraded: the viscosity value dropped to half in 266 
10 minutes. After 20 minutes the degradation process was practically completed as seen by a 267 
reduction in viscosity of 70%. At the same substrate/enzyme ratio, SHL and SHL12 resisted 268 
enzymatic degradation for more than two hours. These results are pointed out in Figure 3A, where 269 
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degradation kinetics and their corresponding baseline (in the absence of enzyme) are plotted. 270 
Moreover, it was surprisingly found that SHLS12 maintained its gel nature, as shown in Figure 3B. 271 
Indeed, the storage modulus value was found to not vary over 2 hours at the substrate/enzyme ratio 272 
tested. 273 
 274 
Figure 3. (A) Degradation kinetics (full symbols) and baselines (open symbols) reported as 275 
viscosity of SHLS12 (red circles), Sodium Hyaluronate-Lipoate (blue circles) and Sodium 276 
Hyaluronate (black circles). (B) Degradation kinetics (full symbols) and baselines (open symbols) 277 
reported as storage (red)/loss (blue) moduli of SHLS12 during hyaluronidase treatment. For all 278 
samples analysed the molar ratio of enzyme/substrate used was 1:6150. 279 
 280 
3.2 Antibacterial properties. The pivotal feature of a silver-containing biomaterial concerns 281 
to its ability to exert antibacterial properties against different bacteria strains without impairing the 282 
viability of eukaryotic cells. In this study, we have explored the possibility by SHLS12 to affect the 283 
growth and viability of bacteria both in a planktonic and in an organized community state (biofilm). 284 
E. coli, S. aureus, P. aeruginosa and S. epidermidis strains were selected for this study because of 285 
their widespread diffusion and high probability to be engaged at an injury site in the human body 286 
and to favor the planktonic-sessile state transition. Figure 4 shows the results obtained by a growth 287 
inhibition assay. A small amount of SHLS12 (0.2% w/v) showed a marked antibacterial activity 288 
owing to the presence of silver ions whereas the formulation without silver (SHL) demonstrated 289 
lack of antibacterial properties (data not shown). For all strains investigated, a significant drop of 290 
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CFU (at least P < 0.01) was identified for SHLS12-treated samples in comparison with control 291 
(suspension of bacteria grown in broth). This finding is confirmed by visual observations as 292 
reported in Figure 4 E-H, which shows the growth of S. aureus colonies on LB agar for treated and 293 
untreated samples. 294 
 295 
 296 
Figure 4. Growth inhibition rate expressed as Log CFU mL-1 of S. aureus (A), S. epidermidis (B), 297 
E. coli (C) and P. aeruginosa (D) following 4 h of treatment with SHLS12. Statistical differences 298 
were determined by means of Student’s t test. **P < 0.01; ***P < 0.001. S. aureus colonies on LB 299 
agar: diluted 10-4 (E) and diluted 10-5 (F) SHLS12-treated sample; diluted 10-4 (G) and diluted 10-5 300 
(H) control sample. 301 
  302 
Considering in vivo applications of SHLS12, the inactivation of silver by serum proteins can 303 
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be a concern. In particular, serum albumin has been shown to have specific binding sites for metal 304 
ions entering the bloodstream.(Deng, Wang, Zhu, Xu, & Ning, 2010),(Durgadas, Sharma, & 305 
Sreenivasan, 2011),(Duff & Kumar, 2009) They are best characterized for human serum albumin 306 
(HSA) and for bovine serum albumin (BSA), which is often used as a model protein for HSA.(Bal, 307 
Sokołowska, Kurowska, & Faller, 2013) Zhao et al. demonstrated the formation of complexes 308 
between Ag+ and BSA by spectroscopic investigation.(Zhao, Liu, Teng, & Liu, 2011) Ostermeyer 309 
et al. demonstrated that BSA reduces the toxicity of citrate silver nanoparticles by chelating the 310 
silver ions released from silver nanoparticles (AgNPs) and by binding to AgNPs surface thus 311 
preventing NH3-dependent dissolution from occurring.(Ostermeyer, Kostigen Mumuper, Semprini, 312 
& Radniecki, 2013) This phenomenon has also been investigated in a previous contribution by the 313 
authors of the here presented paper where the ability of serum proteins to reduce the antibacterial 314 
features of a colloidal solution of Chitlac-nAg was demonstrated.(E Marsich et al., 2013) It should 315 
be recalled that at physiological pH the overall charge of albumin is predominantly negative, and 316 
hence electrostatic interactions with the Chitlac polycation may be at the root of such an adverse 317 
effect. We selected BSA at a concentration of 40 g L-1 to verify its influence on the antibacterial 318 
properties of SHLS12. As shown in Figure 5, a significant drop of S. aureus and P. aeruginosa 319 
CFUs was demonstrated after 4 h of treatment with both SHLS12 and SHLS12 + BSA with respect 320 
to control. By comparing SHLS12 with SHLS12 + BSA treated samples, no statistical difference 321 
was identified for S. aureus. In the case of P. aeruginosa a significant but small difference was 322 
identified (P < 0.05), so as to evidence only a partial and minimal inhibitory effect of serum 323 
albumin towards SHLS12 antibacterial activity. At variance with the case of Chitlac, a favorable 324 
electrostatic contribution by the anionic nature of the hyaluronan backbone to prevent association 325 
with albumin can be reasonably postulated for SHLS12.   326 
 327 
 328 
 329 
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Figure 5. Growth inhibition rate in the presence/absence of BSA expressed as Log CFU mL-1 of S. 330 
aureus (A) and P. aeruginosa (B) following 4 h of treatment with SHLS12. Statistical differences 331 
were determined by means of Student’s t test. NS no statistical differences between SHLS12 and 332 
SHLS12 + BSA-treated samples; *P < 0.05 between SHLS12 and SHLS12 + BSA-treated samples. 333 
 334 
Another key issue that has been considered in the present work is the capability of the silver-335 
complex to exert antibacterial activity towards organized-community of bacteria, so called biofilms. 336 
In such condition, an extracellular polymeric substance (EPS) surrounds the bacterial cells making 337 
them one thousand times more resistant to antibiotics and drugs than planktonic ones.(Pelgrift & 338 
Friedman, 2013) S. aureus and P. aeruginosa were selected for these studies because of their ability 339 
to form biofilms.(Sacco et al., 2015),(Hindi et al., 2009) Figure 6 A-B summarizes the outcomes 340 
obtained after 4 and 24 h of treatment of S. aureus and P. aeruginosa biofilms, respectively. In both 341 
cases, SHLS12 was effective in breaking apart the biofilm, as revealed by MTT colorimetric assay. 342 
The optical density (OD) of S. aureus treated with SHLS12 showed a reduction of about 30% after 343 
24 h of treatment with respect to the control, whereas no statistical difference was observed after 4 344 
h of treatment. As contrast, in the case of P. aeruginosa, a marked OD reduction was evident 345 
already after 4 h of treatment. It may be argued that P. aeruginosa is more susceptible than S. 346 
aureus strain to Ag+ ions, likely because of their thinner cell wall, which enables silver ions to 347 
penetrate into the bacterial cell more easily.(Huang, Dai, Xuan, Tegos, & Hamblin, 2011) These 348 
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results were confirmed by differential biofilm staining for dead (red) and alive (green) cells and 349 
visualization with confocal laser scanning microscopy after treatment with SHLS12. In Figure 6 C-350 
F P. aeruginosa and S. aureus biofilms appear as a green fluorescent layer indicating the good 351 
bacteria viability in the case of the control. On the contrary, samples of cells treated for 24 h with 352 
SHLS12 evidenced the presence of a non-homogeneous layer of bacteria with few viable green 353 
cells and a lot of reddish/yellow bacteria, thus suggesting cell suffering and biofilm disaggregation. 354 
These findings are in agreement with what evidenced in the viable biomass experiments reported 355 
above. Overall, growth inhibition assays and viable biomass assessment clearly proved antibacterial 356 
properties of SHLS12 thanks to the presence of silver ions which, as reported in literature, exert 357 
their activity (i) by interacting with thiol/phosphorus-groups of the cell wall and the plasma 358 
membrane proteins of bacteria,(Pelgrift & Friedman, 2013),(Travan et al., 2011) causing membrane 359 
damage or (ii) by binding DNA of microbes leading to cell division alterations.(Hindi et al., 2009) 360 
 361 
 362 
 363 
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 364 
 365 
Figure 6. Viable biomass MTT assay expressed as O.D. at 550 nm of S. aureus (A) and P. 366 
aeruginosa (B) following 4 (empty columns) and 24 h (filled columns) of treatment with SHLS12. 367 
Statistical differences were determined by means of Student’s t test. NS no statistical differences 368 
versus control; *P < 0.05 versus control; **P < 0.01 versus control. LSCM images of P. aeruginosa 369 
biofilm: control group (C) and SHLS12-treated sample (D). LSCM images of S. aureus biofilm: 370 
control group (E) and SHLS12-treated sample (F). Biofilms were grown on tissue culture coverslips 371 
in BHI broth plus 3% w/v sucrose and following treated with SHLS12 for 24 hours. For cell 372 
staining, FilmTracer Live/Dead biofilm viability kit (Invitrogen™) was used. Green fluorescence 373 
indicates live cells whereas red and yellow fluorescence refers to dead and suffering ones, 374 
respectively. Scale bar was 50 µm for all images. 375 
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 376 
3.3 Biocompatibility studies. One of the most important challenges in the production of 377 
silver-containing biomaterials concerns their ability to exert antibacterial activity without impairing 378 
the viability of eukaryotic cells. The toxicity of silver for eukaryotic cells is proportional to the 379 
amount of metal present in cell-containing environment, since it is able to cause cellular damages if 380 
the cells can uptake and internalize the metal.(Y.-H. Lee et al., 2014) A key strategy to reduce silver 381 
toxicity resides then in the development of systems capable to avoid - or at least reduce - the release 382 
of silver in a form available to eukaryotic cell uptake, but at the same time, preserve its 383 
antimicrobial activity allowing for the direct interaction of the metal ions with the proteins localized 384 
on the bacterial surface. 385 
Polysaccharide-based matrices loaded with silver nanoparticles have been already described 386 
to prevent an excess of silver release and thus not to affect the viability of mammalian cells.(Sacco 387 
et al., 2015),(Travan et al., 2009),(Eleonora Marsich et al., 2013) In this view, it is plausible that the 388 
amount of released metal in these systems is under the lethal dose limit and thus not cytotoxic. In 389 
order to assess the biocompatibility of SHLS12, a Neutral Red cytotoxicity assay was carried out. It 390 
is based on the ability of viable cells to incorporate and bind the Neutral Red Supravital dye into the 391 
lysosomes.(Repetto, del Peso, & Zurita, 2008) Viable cells take up the dye by active transport 392 
whereas non-viable cells do not. Keratinocytes (HaCaT) and fibroblasts (NIH-3T3) cell lines were 393 
selected because of their broad use as models to evaluate the response of biological systems towards 394 
biopolymer networks.(Barui, Khare, Dhara, Banerjee, & Chatterjee, 2014) As reported in Figure 7, 395 
SHLS12 did not exert any cytotoxic effect on the cell lines used. In fact, there was no significant 396 
difference in Neutral Red signal between the SHLS12-treated and untreated cells after 24 and 72 h. 397 
The results of the positive control group on NIH-3T3 cells showed an apparently inexplicable 398 
result, namely a similar percentage of viability as the negative control after 4 h of treatment. 399 
However, this is likely ascribed to the slow developing cytotoxic activity of zinc 400 
dibuthyldithiocarbamate in poly(urethane) films towards such cell line. In spite of this, cells 401 
 20 
appeared to be suffering by optical microscopy analyses: changes in morphology and appearance of 402 
suffering signals as well as chromatin aggregation (data not shown). At 72 h the cytotoxicity of the 403 
positive control was clear in all cases. The combination of the results shows that SHLS12, besides 404 
providing a good antibacterial activity against biofilm-forming bacteria strains, is not harmful to 405 
mammalian cells likely because its silver ions are firmly coordinated and immobilized by the 406 
lipoate groups and therefore do not diffuse into the surrounding environment. 407 
 408 
Figure 7. Percentage of viability of fibroblast NIH-3T3 (A) and ketatinocytes HaCaT (B) cells 409 
measured using Neutral Red assay. SHLS12 was kept in touch with cells and testing was performed 410 
after 24 (empty columns) and 72 h (filled columns) of treatment. Poly(urethane) sheets containing 411 
0.25% zinc dibuthyldithiocarbamate were used as contact positive control (C+) whereas plastic 412 
poly(styrene) sheets were used as contact negative control (C-). Statistical differences were 413 
determined by means of Student’s t test. 414 
 415 
4. Conclusions 416 
According to the chemical-physical studies, SHLS12 shows a strong viscoelastic behavior, in 417 
contrast to its polysaccharide precursor, thus suggesting the formation of a network with silver ions 418 
as linking points between the sulphur atoms of the lipoic residues. The overall result is a gel which 419 
is resistant to enzymatic degradation. This property should confer to the material an improved 420 
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biological stability in vivo. Such features, together with the demonstrated antibacterial properties 421 
and lack of cytotoxicity towards eukaryotic cells, allow considering SHLS12 a promising bioactive 422 
system for further in vivo applications. 423 
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